AKT1 and cancer: The distinct nuclear PIPn-p53 signaling pathway, independent of canonical membrane-bound AKT activation and unaffected by existing PI3K inhibitors, highlights the potential for innovative therapeutic interventions that target these specific interactions in cancer treatment.